318 related articles for article (PubMed ID: 20878064)
1. Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts.
D'Assoro AB; Leontovich A; Amato A; Ayers-Ringler JR; Quatraro C; Hafner K; Jenkins RB; Libra M; Ingle J; Stivala F; Galanis E; Salisbury JL
Int J Oncol; 2010 Nov; 37(5):1167-76. PubMed ID: 20878064
[TBL] [Abstract][Full Text] [Related]
2. Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts.
D'Assoro AB; Busby R; Acu ID; Quatraro C; Reinholz MM; Farrugia DJ; Schroeder MA; Allen C; Stivala F; Galanis E; Salisbury JL
Oncogene; 2008 Jun; 27(28):3901-11. PubMed ID: 18264135
[TBL] [Abstract][Full Text] [Related]
3. NOTCH3 expression is linked to breast cancer seeding and distant metastasis.
Leontovich AA; Jalalirad M; Salisbury JL; Mills L; Haddox C; Schroeder M; Tuma A; Guicciardi ME; Zammataro L; Gambino MW; Amato A; Di Leonardo A; McCubrey J; Lange CA; Liu M; Haddad T; Goetz M; Boughey J; Sarkaria J; Wang L; Ingle JN; Galanis E; D'Assoro AB
Breast Cancer Res; 2018 Sep; 20(1):105. PubMed ID: 30180881
[TBL] [Abstract][Full Text] [Related]
4. The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer.
Raza U; Saatci Ö; Uhlmann S; Ansari SA; Eyüpoğlu E; Yurdusev E; Mutlu M; Ersan PG; Altundağ MK; Zhang JD; Doğan HT; Güler G; Şahin Ö
Oncotarget; 2016 Aug; 7(31):49859-49877. PubMed ID: 27409664
[TBL] [Abstract][Full Text] [Related]
5. The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression.
Lo PK; Lee JS; Liang X; Sukumar S
Cell Signal; 2016 Oct; 28(10):1502-19. PubMed ID: 27377963
[TBL] [Abstract][Full Text] [Related]
6. The role of p53-microRNA 200-Moesin axis in invasion and drug resistance of breast cancer cells.
Alam F; Mezhal F; El Hasasna H; Nair VA; Aravind SR; Saber Ayad M; El-Serafi A; Abdel-Rahman WM
Tumour Biol; 2017 Sep; 39(9):1010428317714634. PubMed ID: 28933253
[TBL] [Abstract][Full Text] [Related]
7. Differentiated pre-adipocytes promote proliferation, migration and epithelial-mesenchymal transition in breast cancer cells of different p53 status.
Avşar Abdik E
Mol Biol Rep; 2021 Jun; 48(6):5187-5198. PubMed ID: 34213707
[TBL] [Abstract][Full Text] [Related]
8. BRD7 suppresses invasion and metastasis in breast cancer by negatively regulating YB1-induced epithelial-mesenchymal transition.
Niu W; Luo Y; Zhou Y; Li M; Wu C; Duan Y; Wang H; Fan S; Li Z; Xiong W; Li X; Li G; Ren C; Li H; Zhou M
J Exp Clin Cancer Res; 2020 Feb; 39(1):30. PubMed ID: 32028981
[TBL] [Abstract][Full Text] [Related]
9. Wild-type p53 inhibits pro-invasive properties of TGF-β3 in breast cancer, in part through regulation of EPHB2, a new TGF-β target gene.
Lam S; Wiercinska E; Teunisse AF; Lodder K; ten Dijke P; Jochemsen AG
Breast Cancer Res Treat; 2014 Nov; 148(1):7-18. PubMed ID: 25257729
[TBL] [Abstract][Full Text] [Related]
10. Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint.
D'Assoro AB; Busby R; Suino K; Delva E; Almodovar-Mercado GJ; Johnson H; Folk C; Farrugia DJ; Vasile V; Stivala F; Salisbury JL
Oncogene; 2004 May; 23(23):4068-75. PubMed ID: 15064746
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.
Neilsen PM; Noll JE; Mattiske S; Bracken CP; Gregory PA; Schulz RB; Lim SP; Kumar R; Suetani RJ; Goodall GJ; Callen DF
Oncogene; 2013 Jun; 32(24):2992-3000. PubMed ID: 22797073
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells.
Leontovich AA; Salisbury JL; Veroux M; Tallarita T; Billadeau D; McCubrey J; Ingle J; Galanis E; D'Assoro AB
Oncol Rep; 2013 May; 29(5):1785-8. PubMed ID: 23446853
[TBL] [Abstract][Full Text] [Related]
13. GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner.
Lin F; Xie YJ; Zhang XK; Huang TJ; Xu HF; Mei Y; Liang H; Hu H; Lin ST; Luo FF; Lang YH; Peng LX; Qian CN; Huang BJ
J Exp Clin Cancer Res; 2019 Apr; 38(1):152. PubMed ID: 30961661
[TBL] [Abstract][Full Text] [Related]
14. RNA-binding protein RNPC1: acting as a tumor suppressor in breast cancer.
Xue JQ; Xia TS; Liang XQ; Zhou W; Cheng L; Shi L; Wang Y; Ding Q
BMC Cancer; 2014 May; 14():322. PubMed ID: 24884756
[TBL] [Abstract][Full Text] [Related]
15. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance.
Tsou SH; Chen TM; Hsiao HT; Chen YH
PLoS One; 2015; 10(1):e0116747. PubMed ID: 25635866
[TBL] [Abstract][Full Text] [Related]
16. Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo.
Ziegler E; Hansen MT; Haase M; Emons G; Gründker C
Breast Cancer Res Treat; 2014 Nov; 148(2):269-77. PubMed ID: 25292421
[TBL] [Abstract][Full Text] [Related]
17. FUT8 promotes breast cancer cell invasiveness by remodeling TGF-β receptor core fucosylation.
Tu CF; Wu MY; Lin YC; Kannagi R; Yang RB
Breast Cancer Res; 2017 Oct; 19(1):111. PubMed ID: 28982386
[TBL] [Abstract][Full Text] [Related]
18. Gain-of-function of mutant p53: mutant p53 enhances cancer progression by inhibiting KLF17 expression in invasive breast carcinoma cells.
Ali A; Shah AS; Ahmad A
Cancer Lett; 2014 Nov; 354(1):87-96. PubMed ID: 25111898
[TBL] [Abstract][Full Text] [Related]
19. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin.
Hugo HJ; Gunasinghe NPAD; Hollier BG; Tanaka T; Blick T; Toh A; Hill P; Gilles C; Waltham M; Thompson EW
Breast Cancer Res; 2017 Jul; 19(1):86. PubMed ID: 28750639
[TBL] [Abstract][Full Text] [Related]
20. The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition.
Fredlund E; Staaf J; Rantala JK; Kallioniemi O; Borg A; Ringnér M
Breast Cancer Res; 2012 Jul; 14(4):R113. PubMed ID: 22839103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
